Drugs / Necuparanib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01621243 | May 2012 → Oct 2016 | malignant pancreatic neoplasm | Momenta Pharmaceuticals, Inc. | Terminated | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Necuparanib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01621243 ↗ |
| Known as | M402 | “called necuparanib (M402)” NCT01621243 ↗ |
| Modality | Other / unclassified | “Necuparanib, a rationally engineered low-molecular-weight heparin” PMID 32361265 ↗ Apr 2020 |
| Route | Subcutaneous | “necuparanib (5 mg/kg subcutaneous injection once daily)” PMID 32361265 ↗ Apr 2020 |